RxDoctor Payments Data

Alexis Wolfe, MD

Pulmonary Disease · Chicago, ILNPI 1447690961

Payments from drug & device makers

$662in general payments, 2019–2025

Across 16 payments — averaging $41.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$226
  • Boehringer Ingelheim$190
  • Lilly USA, LLC$96
  • Philips North America LLC$93
  • Medtronic$37
  • Merz Pharmaceuticals, LLC$20

What the payments were for

  • Food & beverage$61092%
  • Education$538%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$662 in reported general payments places this provider in the 40th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$84,282
Medicare patients
353
Services billed
788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$87,927
Breo ElliptaFluticasone/Vilanterol75$49,256
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$45,401
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr60$37,845
Advair HfaFluticasone Propion/Salmeterol77$35,392
Spiriva RespimatTiotropium Bromide17$13,484
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$11,982
Arnuity ElliptaFluticasone Furoate35$10,101
Incruse ElliptaUmeclidinium Bromide24$9,532
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$7,386
Spiriva HandihalerTiotropium Bromide12$5,863
SymbicortBudesonide/Formoterol Fumarate14$5,661
Advair DiskusFluticasone Propion/Salmeterol14$3,973
Albuterol Sulfate HfaAlbuterol Sulfate100$3,414
Asmanex HfaMometasone Furoate12$1,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Symbicort$226$51,06169 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$190$25,46636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →